124 related articles for article (PubMed ID: 34969757)
1. Blockade of GRP78 Translocation to the Cell Surface by HDAC6 Inhibition Suppresses Proliferation of Cholangiocarcinoma Cells.
Kim C; Lee S; Kim D; Lee DS; Lee E; Yoo C; Kim KP
Anticancer Res; 2022 Jan; 42(1):471-482. PubMed ID: 34969757
[TBL] [Abstract][Full Text] [Related]
2. HDAC6-dependent ciliophagy is involved in ciliary loss and cholangiocarcinoma growth in human cells and murine models.
Peixoto E; Jin S; Thelen K; Biswas A; Richard S; Morleo M; Mansini A; Holtorf S; Carbone F; Pastore N; Ballabio A; Franco B; Gradilone SA
Am J Physiol Gastrointest Liver Physiol; 2020 Jun; 318(6):G1022-G1033. PubMed ID: 32338033
[TBL] [Abstract][Full Text] [Related]
3. Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways.
Cao J; Lv W; Wang L; Xu J; Yuan P; Huang S; He Z; Hu J
Cell Death Dis; 2018 Jul; 9(8):817. PubMed ID: 30050135
[TBL] [Abstract][Full Text] [Related]
4. ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.
Wang F; Zhong BW; Zhao ZR
J Biol Regul Homeost Agents; 2018; 32(4):851-858. PubMed ID: 30043566
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of histone deacetylase 6 destabilizes ERK phosphorylation and suppresses cancer proliferation via modulation of the tubulin acetylation-GRP78 interaction.
Wattanathamsan O; Chantaravisoot N; Wongkongkathep P; Kungsukool S; Chetprayoon P; Chanvorachote P; Vinayanuwattikun C; Pongrakhananon V
J Biomed Sci; 2023 Jan; 30(1):4. PubMed ID: 36639650
[TBL] [Abstract][Full Text] [Related]
6. HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.
Laino AS; Betts BC; Veerapathran A; Dolgalev I; Sarnaik A; Quayle SN; Jones SS; Weber JS; Woods DM
J Immunother Cancer; 2019 Feb; 7(1):33. PubMed ID: 30728070
[TBL] [Abstract][Full Text] [Related]
7. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
Santo L; Hideshima T; Kung AL; Tseng JC; Tamang D; Yang M; Jarpe M; van Duzer JH; Mazitschek R; Ogier WC; Cirstea D; Rodig S; Eda H; Scullen T; Canavese M; Bradner J; Anderson KC; Jones SS; Raje N
Blood; 2012 Mar; 119(11):2579-89. PubMed ID: 22262760
[TBL] [Abstract][Full Text] [Related]
8. Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells.
Vekaria PH; Kumar A; Subramaniam D; Dunavin N; Vallurupalli A; Schoenen F; Ganguly S; Anant S; McGuirk JP; Jensen RA; Rao R
Leukemia; 2019 Jul; 33(7):1675-1686. PubMed ID: 30664664
[TBL] [Abstract][Full Text] [Related]
9. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
10. Ricolinostat (ACY-1215) inhibits VEGF expression via PI3K/AKT pathway and promotes apoptosis in osteoarthritic osteoblasts.
Li L; Liu F; Huang W; Wang J; Wan Y; Li M; Pang Y; Yin Z
Biomed Pharmacother; 2019 Oct; 118():109357. PubMed ID: 31548177
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
12. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
Lorenzo Pisarello M; Masyuk TV; Gradilone SA; Masyuk AI; Ding JF; Lee PY; LaRusso NF
Am J Pathol; 2018 Apr; 188(4):981-994. PubMed ID: 29366679
[TBL] [Abstract][Full Text] [Related]
13. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
[TBL] [Abstract][Full Text] [Related]
14. The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma.
Lee DH; Kim GW; Kwon SH
Mol Carcinog; 2019 Jun; 58(6):944-956. PubMed ID: 30693983
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib.
Amengual JE; Prabhu SA; Lombardo M; Zullo K; Johannet PM; Gonzalez Y; Scotto L; Serrano XJ; Wei Y; Duong J; Nandakumar R; Cremers S; Verma A; Elemento O; O'Connor OA
Clin Cancer Res; 2017 Jun; 23(12):3084-3096. PubMed ID: 27993968
[No Abstract] [Full Text] [Related]
16. PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition.
Meng Z; Jia LF; Gan YH
Oncogene; 2016 May; 35(18):2333-44. PubMed ID: 26279303
[TBL] [Abstract][Full Text] [Related]
17. Low levels of pyruvate induced by a positive feedback loop protects cholangiocarcinoma cells from apoptosis.
Zhang M; Pan Y; Tang D; Dorfman RG; Xu L; Zhou Q; Zhou L; Wang Y; Li Y; Yin Y; Kong B; Friess H; Zhao S; Wu JL; Wang L; Zou X
Cell Commun Signal; 2019 Mar; 17(1):23. PubMed ID: 30866966
[TBL] [Abstract][Full Text] [Related]
18. Thymoquinone induces G2/M arrest, inactivates PI3K/Akt and nuclear factor-κB pathways in human cholangiocarcinomas both in vitro and in vivo.
Xu D; Ma Y; Zhao B; Li S; Zhang Y; Pan S; Wu Y; Wang J; Wang D; Pan H; Liu L; Jiang H
Oncol Rep; 2014 May; 31(5):2063-70. PubMed ID: 24603952
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of HDAC6 attenuates LPS-induced inflammation in macrophages by regulating oxidative stress and suppressing the TLR4-MAPK/NF-κB pathways.
Zhang WB; Yang F; Wang Y; Jiao FZ; Zhang HY; Wang LW; Gong ZJ
Biomed Pharmacother; 2019 Sep; 117():109166. PubMed ID: 31255993
[TBL] [Abstract][Full Text] [Related]
20. HDAC6 inhibitor ACY-1215 enhances STAT1 acetylation to block PD-L1 for colorectal cancer immunotherapy.
Wen Y; Ye S; Li Z; Zhang X; Liu C; Wu Y; Zheng R; Xu C; Tian J; Shu L; Yan Q; Ai F; Ma J
Cancer Immunol Immunother; 2024 Jan; 73(1):7. PubMed ID: 38231305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
